当前位置: X-MOL 学术J. Urol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
A Phase II Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder.
The Journal of Urology ( IF 5.9 ) Pub Date : 2024-04-23 , DOI: 10.1097/ju.0000000000003977
Sunil H Patel 1 , Andrew T Gabrielson 1 , Sin Chan 1 , Deborah Schwartz 1 , Connie Collins 1 , Nirmish Singla 1 , Bruce Trock 1 , Trinity J Bivalacqua 2 , Noah Hahn 1, 3 , Max R Kates 1
Affiliation  

Combination intravesical gemcitabine and docetaxel (GemDoce) has demonstrated efficacy as second-line therapy for patients with bacillus Calmette-Guérin (BCG)‒unresponsive nonmuscle-invasive urothelial carcinoma of the bladder (NMIBC). In the context of widespread BCG shortages, we performed a phase 2 prospective trial to assess GemDoce for BCG-naïve NMIBC.

中文翻译:


膀胱内注射吉西他滨和多西他赛治疗卡介苗-幼稚非肌肉浸润性膀胱尿路上皮癌的 II 期试验。



膀胱内注射吉西他滨和多西紫杉醇 (GemDoce) 组合已被证明作为卡介苗 (BCG) 无反应性非肌层浸润性膀胱尿路上皮癌 (NMIBC) 患者的二线治疗有效。在 BCG 普遍短缺的情况下,我们进行了一项 2 期前瞻性试验,以评估 GemDoce 对未使用 BCG 的 NMIBC 的疗效。
更新日期:2024-04-23
down
wechat
bug